Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), e non (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), e non (Expand Search)
-
121
-
122
-
123
Upcycling of Postconsumer Recyclate Polypropylene into Low Warping and High Toughness 3D Printable Filaments
Published 2025“…Polypropylene (PP) is widely used in commodity applications owing to its chemical stability, mechanical properties and low cost. However, almost 50% of the produced PP ends up as postconsumer waste (PCW) within a short period of usage. …”
-
124
Upcycling of Postconsumer Recyclate Polypropylene into Low Warping and High Toughness 3D Printable Filaments
Published 2025“…Polypropylene (PP) is widely used in commodity applications owing to its chemical stability, mechanical properties and low cost. However, almost 50% of the produced PP ends up as postconsumer waste (PCW) within a short period of usage. …”
-
125
Data_Sheet_1_Effectiveness of non-pharmaceutical interventions in nine fields of activity to decrease SARS-CoV-2 transmission (Spain, September 2020–May 2021).PDF
Published 2023“…Background<p>We estimated the association between the level of restriction in nine different fields of activity and SARS-CoV-2 transmissibility in Spain, from 15 September 2020 to 9 May 2021.</p>Methods<p>A stringency index (0–1) was created for each Spanish province (n = 50) daily. …”
-
126
-
127
-
128
-
129
-
130
-
131
-
132
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
133
-
134
-
135
-
136
-
137
-
138
-
139
Drugs susceptibility profile (EC<sub>50</sub> values and Fold-change) to the antileishmanials in all polyene resistant lines of <i>Leishmania</i> spp.
Published 2022“…<p>Mean EC<sub>50</sub> values (μM) ± Standard Deviation (SD). …”
-
140